Skip to main content

Advertisement

SpringerLink
Log in

Cardiogenic shock in cancer

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Cardiogenic shock (CS) is increasingly recognized in patients with malignancies, while cancer is independently associated with worse prognosis in CS. A number of conditions may lead to CS in cancer, including acute coronary syndromes, cardiomyopathy, takotsubo syndrome, myocarditis, pulmonary embolism, tamponade, and cardiac herniation. In these conditions, CS may be related to cancer itself or to cancer therapy, including surgery, chemotherapy, or radiotherapy. Given the significantly improved overall survival of patients with malignancies, the early recognition and proper management of CS in cancer become increasingly important. In the present paper, we review the available evidence on CS in patients with malignancies and highlight issues related to its management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tubaro M, Vranckx P, Price S, Vrints C, European Society of C. The ESC textbook of intensive and acute cardiovascular care. 2016

  2. Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, on behalf of the ESC Heart Failure Long-Term Registry Investigators (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(10):1242–1254

    Article  PubMed  Google Scholar 

  3. Puymirat E, Fagon JY, Aegerter P et al (2017) Cardiogenic shock in intensive care units: evolution of prevalence, patient profile, management and outcomes, 1997–2012. Eur J Heart Failure 19(2):192–200

    Article  Google Scholar 

  4. Shaefi S, O’Gara B, Kociol RD, Joynt K, Mueller A, Nizamuddin J, Mahmood E, Talmor D, Shahul S (2015) Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. J Am Heart Assoc 4(1):e001462

    Article  PubMed  PubMed Central  Google Scholar 

  5. Rodriguez M, Sabharwal B, Wei X, Krittanawong C, Verheyen E, Herzog E. The effect of cancer on outcomes on acute heart failure exacerbations: a 5-year nationwide analysis. 2018;71(11 Supplement):A693

  6. Iliescu CA, Grines CL, Herrmann J et al (2016) SCAI expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of India, and sociedad Latino Americana de Cardiologia intervencionista). Catheter Cardiovasc Interv 87(5):E202–E223

    Article  PubMed  Google Scholar 

  7. Park JY, Al-Hijji M, El Sabbagh A et al (2016) Acute coronary syndrome in active hematological malignancies: a cohort study of 5,300 patients. JACC 67(13 Supplement):585

    Article  Google Scholar 

  8. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM (2017) Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 70(8):926–938

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lim SH, Wilson SM, Hunter A, Hill J, Beale P (2013) Takotsubo cardiomyopathy and 5-fluorouracil: getting to the heart of the matter. Case Rep Oncol Med 2013:206765

    PubMed  PubMed Central  Google Scholar 

  10. Rohrmann S, Witassek F, Erne P, Rickli H, Radovanovic D (2018) Treatment of patients with myocardial infarction depends on history of cancer. Eur Heart J Acute Cardiovasc Care 7(7):639–645

    Article  PubMed  Google Scholar 

  11. Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AACM, Cannegieter SC, Jukema JW, Umans VAWM, Schalij MJ, van Boven AJ (2013) Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 112(12):1867–1872

    Article  PubMed  Google Scholar 

  12. Sulpher J, Dattilo F, Dent S, Turek M, Reaume MN, Johnson C. Acute cardiogenic shock induced by infusional 5-fluorouracil. Case Rep Oncol Med 2014;2014:819396

    Article  Google Scholar 

  13. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016;37(36):2768–2801

    Article  PubMed  Google Scholar 

  14. Manual of cardio-oncology. Cardiovascular care in the cancer patient. 2017 ed: Springer International Publishing Switzerland 2017; 2017

  15. Ozaki T, Chiba S, Annen K, Kawamukai Y, Kohno N, Horimoto M (2010) Acute coronary syndrome due to coronary artery compression by a metastatic cardiac tumor. J Cardiol Cases 1(1):e52–ee5

    Article  PubMed  Google Scholar 

  16. Nogales-Romo MT, Tirado G, Freitas-Ferraz A, Martínez-Losas P, Rodrigo JL, Alswies A, Saiz-Pardo M, Ruiz-Mateos B, Viana-Tejedor A, Fernández-Ortiz A, Macaya C, Núñez-Gil IJ (2016) Coronary embolism of left atrial myxoma coexisting with severe aortic stenosis and atherosclerotic coronary disease. Int J Cardiol 203:315–316

    Article  PubMed  Google Scholar 

  17. Noguchi M, Yamada Y, Sakakura K, Katayama T, Momomura S, Ako J (2016) Coronary thrombus aspiration revealed tumorous embolism of myxofibrosarcoma from the left atrium. Cardiovasc Interv Ther 31(1):75–78

    Article  PubMed  Google Scholar 

  18. Antonopoulos AS, Chrysohoou C, Lymperiadis D, Brili S, Tousoulis D (2016) Peripheral and coronary artery embolisms due to left ventricle fibroelastoma. Hell J Cardiol 57(5):368–370

    Article  Google Scholar 

  19. Aronson D, Brenner B (2018) Arterial thrombosis and cancer. Thromb Res 164(Suppl 1):S23–Ss8

    Article  CAS  PubMed  Google Scholar 

  20. Farmakis D, Mantzourani M, Filippatos G (2018) Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail 20(5):907–909

    Article  PubMed  Google Scholar 

  21. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 131(22):1981–1988

    Article  CAS  PubMed  Google Scholar 

  22. Ghadri JR, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, Cammann VL, Crea F, Galiuto L, Desmet W, Yoshida T, Manfredini R, Eitel I, Kosuge M, Nef HM, Deshmukh A, Lerman A, Bossone E, Citro R, Ueyama T, Corrado D, Kurisu S, Ruschitzka F, Winchester D, Lyon AR, Omerovic E, Bax JJ, Meimoun P, Tarantini G, Rihal C, Y.-Hassan S, Migliore F, Horowitz JD, Shimokawa H, Lüscher TF, Templin C International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 2018;39(22):2032–2046

    Article  PubMed  PubMed Central  Google Scholar 

  23. Giza DE, Lopez-Mattei J, Vejpongsa P et al (2017) Stress-induced cardiomyopathy in cancer patients. Am J Cardiol 120(12):2284–2288

    Article  PubMed  Google Scholar 

  24. Munoz E, Iliescu G, Vejpongsa P, Charitakis K, Karimzad K, Lopez-Mattei J, Yusuf SW, Marmagkiolis K, Iliescu C (2016) Takotsubo stress cardiomyopathy: “good news” in cancer patients? J Am Coll Cardiol 68(10):1143–1144

    Article  PubMed  Google Scholar 

  25. Fernandez SF BM, Canty JM Jr. Takotsubo cardiomyopathy following initial chemotherapy presenting with syncope and cardiogenic shock – a case report and literature review. J Clin Exp Cardiol 2:124 2011

  26. Burgdorf C, Kurowski V, Bonnemeier H, Schunkert H, Radke PW (2008) Long-term prognosis of the transient left ventricular dysfunction syndrome (Tako-Tsubo cardiomyopathy): focus on malignancies. Eur J Heart Fail 10(10):1015–1019

    Article  PubMed  Google Scholar 

  27. Madias JE (2016) What is/are the trigger(s) of takotsubo syndrome in cancer patients receiving chemotherapy? Int J Cardiol 222:253

    Article  PubMed  Google Scholar 

  28. Franco TH, Khan A, Joshi V, Thomas B (2008) Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer. Ther Clin Risk Manag 4(6):1367–1370

    Article  PubMed  PubMed Central  Google Scholar 

  29. Santos JRU, Brofferio A, Viana B, Pacak K (2018) Catecholamine-induced cardiomyopathy in pheochromocytoma: how to manage a rare complication in a rare disease? Horm Metab Res

  30. Bergland BE (1989) Pheochromocytoma presenting as shock. Am J Emerg Med 7(1):44–48

    Article  CAS  PubMed  Google Scholar 

  31. Assefa D, Welsch J, Laubner K, Burgdorf C, Kotzerke M (2015) Cardiogenic shock due to atypical Tako-Tsubo cardiomyopathy in a young woman with pheochromocytoma. Deutsche medizinische Wochenschrift (1946). 140(6):422–425

    Article  Google Scholar 

  32. Chiang YL, Chen PC, Lee CC, Chua SK (2016) Adrenal pheochromocytoma presenting with Takotsubo-pattern cardiomyopathy and acute heart failure: a case report and literature review. Medicine. 95(36):e4846

    Article  PubMed  PubMed Central  Google Scholar 

  33. Di Palma G, Daniele GP, Antonini-Canterin F, Piazza R, Nicolosi GL (2010) Cardiogenic shock with basal transient left ventricular ballooning (Takotsubo-like cardiomyopathy) as first presentation of pheochromocytoma. J Cardiovasc Med (Hagerstown) 11(7):507–510

    Article  Google Scholar 

  34. Law C, Khaliq A, Guglin M (2013) Reversible cardiogenic shock due to catecholamine-induced cardiomyopathy: a variant of takotsubo? Am J Emerg Med 31(11):1621.e1–1621.e3

    Article  Google Scholar 

  35. Hekimian G, Kharcha F, Brechot N et al (2016) Extracorporeal membrane oxygenation for pheochromocytoma-induced cardiogenic shock. Ann Intensive Care 6(1):117

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Flam B, Broome M, Frenckner B, Branstrom R, Bell M (2015) Pheochromocytoma-induced inverted takotsubo-like cardiomyopathy leading to cardiogenic shock successfully treated with extracorporeal membrane oxygenation. J Intensive Care Med 30(6):365–372

    Article  PubMed  Google Scholar 

  37. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, Tabib A, Maujean G, Descotes J, Timour Q (2006) Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 25(6):305–309

    Article  CAS  PubMed  Google Scholar 

  38. Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME (1994) 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 10(8):861–864

    CAS  PubMed  Google Scholar 

  39. Sellier-Leclerc AL, Belli E, Guerin V, Dorfmuller P, Deschenes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28(9):1875–1879

    Article  PubMed  Google Scholar 

  40. Alonso JJ, Canovas A, Rubio G (2013) Lethal enterovirus myocarditis associated with rituximab and chemotherapy for follicular lymphoma. Med Clin 141(10):459–460

    Article  Google Scholar 

  41. Asnani A (2018) Cardiotoxicity of immunotherapy: incidence, diagnosis, and management. Curr Oncol Rep 20(6):44

    Article  PubMed  Google Scholar 

  42. Johnson DB, Balko JM, Compton ML et al (2016) Fulminant myocarditis with combination immune checkpoint blockade. N Eng J Med 375(18):1749–1755

    Article  CAS  Google Scholar 

  43. Sauer R, Kiewe P, Desole M et al (2017) Lymphocytic myocarditis in a patient with metastatic clear cell renal cell carcinoma treated with nivolumab. Pathologe 38(6):535–539

    Article  CAS  PubMed  Google Scholar 

  44. Cheung CC, Constantine M, Ahmadi A, Shiau C, Chen LYC (2017) Eosinophilic myocarditis. Am J Med Sci 354(5):486–492

    Article  PubMed  Google Scholar 

  45. Biedka M, Ziolkowska E, Windorbska W (2012) Acute pulmonary embolus in the course of cancer. Contemp Oncol 16(5):388–393

    Google Scholar 

  46. Silva P, Rosales M, Milheiro MJ, Santos LL (2015) Pulmonary embolism in ambulatory oncologic patients. Acta Med Port 28(4):463–468

    Article  PubMed  Google Scholar 

  47. Bach AG, Neumann J, Taute BM, Surov A (2016) Frequency, cause, and awareness of pulmonary embolism in oncologic patients. Dtsch Med Wochenschr 141(10):713–717

    Article  PubMed  Google Scholar 

  48. Jones DH, Schlatter MG, Cornelius AS, Neirotti RA (2000) A massive pulmonary tumor embolism after surgical manipulation and biopsy of a pelvic mass. Anesth Analg 90(2):322–323

    CAS  PubMed  Google Scholar 

  49. Choi EJ, Jin GY (2017) Pulmonary embolism after percutaneous cryoablation for lung cancer: a case report. J Vasc Interv Radiol 28(9):1285–1287

    Article  PubMed  Google Scholar 

  50. Lin HF, Liao KF, Chang CM, Lin CL, Lai SW, Hsu CY (2018) Correlation of the tamoxifen use with the increased risk of deep vein thrombosis and pulmonary embolism in elderly women with breast cancer: a case-control study. Medicine. 97(51):e12842

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A (2011) Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 16(4):432–444

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Bois MC, Eckhardt MD, Cracolici VM et al (2018) Neoplastic embolization to systemic and pulmonary arteries. J Vasc Surg 68(1):204–212 e7

    Article  PubMed  Google Scholar 

  53. von Herbay A, Illes A, Waldherr R, Otto HF (1990) Pulmonary tumor thrombotic microangiopathy with pulmonary hypertension. Cancer. 66(3):587–592

    Article  Google Scholar 

  54. Han S, Kreit J (2013) 1242: Cardiogenic shock from pulmonary tumor thrombotic microangiopathy. 41(12):A319

  55. Ohguchi H, Imaeda K, Hotta A, Kakoi S, Yasuda S, Shimizu Y, Hayakawa A, Mishina H, Hasegawa C, Ito S, Ogawa K, Yagi T, Koyama H, Tanaka T, Kato H, Takahashi S, Joh T (2018) An autopsy case of pulmonary tumor thrombotic microangiopathy due to rapidly progressing colon cancer in a patient with type 2 diabetes. Intern Med 57(17):2533–2539

    Article  PubMed  PubMed Central  Google Scholar 

  56. Vincent F, Lamblin N, Classe M, Schurtz G, Rauch A, Fertin M, de Groote P (2017) Subacute right heart failure revealing three simultaneous causes of post-embolic pulmonary hypertension in metastatic dissemination of breast cancer. ESC Heart Fail 4(1):75–77

    Article  PubMed  Google Scholar 

  57. Seol SH, Park BM, Jin HY, Kim DI (2013) Fatal acute right heart failure in gastric cancer patients. Heart Views 14(4):179–181

    Article  PubMed  PubMed Central  Google Scholar 

  58. Okubo Y, Wakayama M, Kitahara K, Nemoto T, Yokose T, Abe F, Hiruta N, Sasai D, Shinozaki M, Nakayama H, Ishiwatari T, Shibuya K (2011) Pulmonary tumor thrombotic microangiopathy induced by gastric carcinoma: morphometric and immunohistochemical analysis of six autopsy cases. Diagn Pathol 6:27

    Article  PubMed  PubMed Central  Google Scholar 

  59. Tsujimoto N, Miyoshi A, Mimura M, Naka T, Yamasaki M, Yokoi T (2018) Case report: pulmonary tumor thrombotic microangiopathy in a cervical cancer patient. Gynecol Obstet Investig 83(1):99–104

    Article  Google Scholar 

  60. Purga SL, Narula N, Horn EM, Karas MG (2015) Pulmonary tumour thrombotic microangiopathy as a cause of new-onset pulmonary hypertension in a patient with metastatic low-grade serous ovarian cancer. BMJ Case Rep 2015

  61. Takayama T, Okura Y, Okada Y, Honma K, Nashimoto A, Sato N, Yokoyama A, Minamino T (2015) Characteristics of neoplastic cardiac tamponade and prognosis after pericardiocentesis: a single-center study of 113 consecutive cancer patients. Int J Clin Oncol 20(5):872–877

    Article  PubMed  Google Scholar 

  62. Khan UA, Shanholtz CB, McCurdy MT (2017) Oncologic mechanical emergencies. Hematol Oncol Clin North Am 31(6):927–940

    Article  PubMed  Google Scholar 

  63. Abdelnaby M, Almaghraby A, Saleh Y, Abayazeed R (2018) Pericardial sarcoma. BMJ Case Rep 2018

  64. Chen YY, Huang WC, Huang MH, Lu TM, Hsu CP (2018) The intra-pericardial paraganglioma presenting as ascites and hemopericardium with impending tamponade. Int Heart J 59(3):664–667

    Article  PubMed  Google Scholar 

  65. Nagarsheth NP, Harrison M, Kalir T, Rahaman J (2006) Malignant pericardial effusion with cardiac tamponade in a patient with metastatic vaginal adenocarcinoma. Int J Gynecol Cancer 16(3):1458–1461

    Article  CAS  PubMed  Google Scholar 

  66. Oka Y, Okada K, Miyake Y, et al. [Three cases of gastric cancer with rare presentation of oncologic emergency]. Gan to kagaku ryoho Cancer & chemotherapy 2016;43(12):2398–2400

  67. Chen X, Miao Q, Yu Y et al Blunt trauma-induced pericardial tamponade after video-assisted thoracoscopic surgery. Ann Thorac Surg

  68. Chung MW, Ha SY, Choi JH, Park HJ, Myung DS, Cho SB, Lee WS, Kim JW, Oh HH, Joo YE (2018) Cardiac tamponade after radiofrequency ablation for hepatocellular carcinoma: case report and literature review. Medicine. 97(49):e13532

    Article  PubMed  PubMed Central  Google Scholar 

  69. Gonzalo Baron Esquivias RA (2015) Cardiac management of oncology patients. Springer

  70. Sundaram VR, Abbas T (2018) Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: case report. Medicine. 97(44):e12751

    Article  PubMed  PubMed Central  Google Scholar 

  71. Burkhart T, Keith MCL, Lenneman CAG, Fernando RR (2018) Bortezomib-induced cardiac tamponade in a 49-year-old man. Tex Heart Inst J 45(4):260–263

    Article  PubMed  PubMed Central  Google Scholar 

  72. Asai M, Kato Y, Kawai S, et al. Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report2019

  73. Zhao Y, Liu S (2017) Acute cardiac herniation after left Intrapericardial pneumonectomy. J Cardiothorac Vasc Anesth 31(1):270–273

    Article  PubMed  Google Scholar 

  74. Alimi F, Marzouk M, Mgarrech I, Chemchik H, Limayem F (2016) Cardiac herniation after left intrapericardial pneumonectomy. Asian Cardiovasc Thorac Ann 24(6):590–592

    Article  PubMed  Google Scholar 

  75. Zandberg FT, Verbeke SJ, Snijder RJ, Dalinghaus WH, Roeffel SM, Van Swieten HA (2004) Sudden cardiac herniation 6 months after right pneumonectomy. Ann Thorac Surg 78(3):1095–1097

    Article  PubMed  Google Scholar 

  76. Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM (2017) Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer 5(1):91

    Article  PubMed  PubMed Central  Google Scholar 

  77. Keenan NG, Nicholson AG, Oldershaw PJ (2008) Fatal acute pulmonary hypertension caused by pulmonary tumour thrombotic microangiopathy. Int J Cardiol 124(1):e11–e13

    Article  CAS  PubMed  Google Scholar 

  78. Miyazaki S, Ikeda T, Ito G, Inoue M, Nara K, Nishinaga Y, Hasegawa Y (2017) Pulmonary tumor thrombotic microangiopathy successfully treated with corticosteroids: a case report. J Med Case Rep 11(1):356

    Article  PubMed  PubMed Central  Google Scholar 

  79. Ogawa A, Yamadori I, Matsubara O, Matsubara H (2013) Pulmonary tumor thrombotic microangiopathy with circulatory failure treated with imatinib. Intern Med 52(17):1927–1930

    Article  PubMed  Google Scholar 

  80. Higo K, Kubota K, Takeda A, Higashi M, Ohishi M (2014) Successful antemortem diagnosis and treatment of pulmonary tumor thrombotic microangiopathy. Intern Med 53(22):2595–2599

    Article  PubMed  Google Scholar 

  81. Reynen K, Kockeritz U, Strasser RH (2004) Metastases to the heart. Ann Oncol 15(3):375–381

    Article  CAS  PubMed  Google Scholar 

  82. Lestuzzi C (2010) Neoplastic pericardial disease: old and current strategies for diagnosis and management. World J Cardiol 2(9):270–279

    Article  PubMed  PubMed Central  Google Scholar 

  83. Farmakis D, Keramida K, Filippatos G (2018) How to build a cardio-oncology service? Eur J Heart Fail 20(12):1732–1734

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical School University of Cyprus, Nicosia, Cyprus

    Kalliopi Keramida & Dimitrios Farmakis

  2. Cardio-Oncology Clinic, Heart Failure Unit, Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece

    Kalliopi Keramida, John T. Parissis & Dimitrios Farmakis

  3. Emergency Institute for Cardiovascular Diseases “Prof. C.C.Iliescu”, Bucharest, University of Medicine Carol Davila Bucharest, Bucharest, Romania

    Ovidiu Chioncel

Authors
  1. Kalliopi Keramida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John T. Parissis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ovidiu Chioncel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dimitrios Farmakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kalliopi Keramida.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Keramida, K., Parissis, J.T., Chioncel, O. et al. Cardiogenic shock in cancer. Heart Fail Rev 24, 997–1004 (2019). https://doi.org/10.1007/s10741-019-09819-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-019-09819-9

Keywords

Search

Navigation